Results 31 to 40 of about 20,527 (318)
JEADV Clinical Practice, 2023 Background In a recent post hoc analysis of multinational clinical trial data, dupilumab treatment for patients with moderate or severe atopic dermatitis (AD) reduced all‐cause and AD‐related hospitalisations.
Ken Igawa +6 more
doaj +1 more source
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
ERJ Open Research, 2023 Background The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients ≥12
Jonathan Corren +12 more
doaj +1 more source
Dupilumab: A new paradigm for the treatment of allergic diseases [PDF]
, 2018 Moderate and severe forms of allergic diseases such as atopic dermatitis and asthma are a challenge for clinicians. In these conditions, which severely affect the quality of life of the patient and frequently have associated allergic comorbidities, the ...
Dávila, Ignacio, Sastre, Joaquín
core +2 more sources
Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series
Journal of Allergy and Clinical Immunology: Global, 2023 This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis.
Shuhei Hara, MD +5 more
doaj
Conjunctivitis in patients with atopic dermatitis treated with dupilumab
Drugs in Context, 2020 Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL- 13 are key cytokines in the immunopathogenesis of AD.
Sandra Ferreira, Tiago Torres
doaj +1 more source
Journal of Cutaneous Immunology and Allergy, 2023 Objectives Alopecia areata (AA) often coexists with atopic dermatitis (AD). Recently, several reports suggested that dupilumab, an interleukin 4 receptor α‐antagonist, administration could be a promising medication not only for severe AD but also for AA ...
Masahiro Fukuyama +3 more
doaj +1 more source
Cicatricial ectropion in a patient treated with dupilumab
American Journal of Ophthalmology Case Reports, 2017 Purpose: To describe a case of bilateral conjunctivitis and cicatricial ectropion associated with dupilumab therapy for atopic dermatitis. Observations: Severe hyperemia of the conjunctiva and eyelid margins, as well as cicatricial ectropion, began two ...
Alexander C. Barnes +2 more
doaj +1 more source
Severe Atopic Dermatitis In Spain: A Real-Life Observational Study [PDF]
, 2019 Objective: To determine the epidemiology and characterize the treatment prescribed for severe atopic dermatitis (AD) in children/adults in usual clinical practice.
Armario Hita, José Carlos +2 more
core +2 more sources
Dupilumab-associated cicatrizing ocular disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: To describe three cases of bilateral cicatrizing conjunctivitis associated with dupilumab treatment for atopic dermatitis. Observations: Case 1 is a 69 year-old male with a history of mild, stable cicatrizing conjunctivitis thought to be ...
Amit K. Reddy +4 more
doaj
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
Frontiers in Immunology, 2021 BackgroundBullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed.
Yihua Zhang +7 more
doaj +1 more source